MA53447A - Tensioactifs résistant à la dégradation de lipase destinés à être utilisés dans des formulations thérapeutiques à grande molécule - Google Patents

Tensioactifs résistant à la dégradation de lipase destinés à être utilisés dans des formulations thérapeutiques à grande molécule

Info

Publication number
MA53447A
MA53447A MA053447A MA53447A MA53447A MA 53447 A MA53447 A MA 53447A MA 053447 A MA053447 A MA 053447A MA 53447 A MA53447 A MA 53447A MA 53447 A MA53447 A MA 53447A
Authority
MA
Morocco
Prior art keywords
large molecule
therapeutic formulations
molecule therapeutic
degradation resistant
lipase degradation
Prior art date
Application number
MA053447A
Other languages
English (en)
Inventor
Steven Labrenz
Patrick Stahl
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA53447A publication Critical patent/MA53447A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01001—Carboxylesterase (3.1.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
MA053447A 2018-08-23 2019-08-22 Tensioactifs résistant à la dégradation de lipase destinés à être utilisés dans des formulations thérapeutiques à grande molécule MA53447A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862721884P 2018-08-23 2018-08-23

Publications (1)

Publication Number Publication Date
MA53447A true MA53447A (fr) 2021-09-15

Family

ID=69587008

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053447A MA53447A (fr) 2018-08-23 2019-08-22 Tensioactifs résistant à la dégradation de lipase destinés à être utilisés dans des formulations thérapeutiques à grande molécule

Country Status (8)

Country Link
US (2) US20200061015A1 (fr)
EP (2) EP4371568A3 (fr)
KR (1) KR20210049842A (fr)
CN (1) CN112601518A (fr)
ES (1) ES2977866T3 (fr)
IL (1) IL280862A (fr)
MA (1) MA53447A (fr)
WO (1) WO2020039384A1 (fr)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3300624C2 (de) * 1983-01-11 1984-11-15 Danfoss A/S, Nordborg Ventil mit Voreinstellung der Durchflußmenge
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
CA2490411A1 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1971366B1 (fr) 2005-12-29 2014-07-30 Janssen Biotech, Inc. Anticorps humains anti-il-23, compositions, procedes et utilisations afferents
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
BR112015008186A2 (pt) * 2012-10-25 2017-09-19 Medimmune Llc formulação de um anticorpo estável e de baixa viscosidade
HUE041499T2 (hu) 2012-11-21 2019-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
EP3310386B1 (fr) 2015-06-22 2021-07-21 Janssen Biotech, Inc. Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
SI3337502T1 (sl) * 2015-08-19 2020-10-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
EP3408293A4 (fr) 2016-01-28 2019-09-11 Janssen Biotech, Inc. Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
WO2018096445A1 (fr) * 2016-11-22 2018-05-31 Biocon Limited Formulation stable d'anticorps monoclonal humanisé recombiné

Also Published As

Publication number Publication date
KR20210049842A (ko) 2021-05-06
EP3840726A4 (fr) 2022-06-08
EP3840726B1 (fr) 2024-04-03
EP4371568A2 (fr) 2024-05-22
WO2020039384A1 (fr) 2020-02-27
EP3840726C0 (fr) 2024-04-03
EP4371568A3 (fr) 2024-09-11
US20220265596A1 (en) 2022-08-25
ES2977866T3 (es) 2024-09-02
EP3840726A1 (fr) 2021-06-30
US20200061015A1 (en) 2020-02-27
CN112601518A (zh) 2021-04-02
IL280862A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
MA41805A (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre diverses tumeurs
MA45073A (fr) Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA46430A (fr) Thérapie combinée d'agonistes de cnp à libération contrôlée
MA41159A (fr) Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
MA53548A (fr) Formulations antiparasitaires de goût agréable
MA55821A (fr) Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression
MA55015A (fr) Formulations pharmaceutiques
MA44987A (fr) Formulations de médicaments améliorées
MA49618A (fr) Inhibiteurs de la mpo destinés à être utilisés en médecine
MA53447A (fr) Tensioactifs résistant à la dégradation de lipase destinés à être utilisés dans des formulations thérapeutiques à grande molécule
MA45451A (fr) Formulations tensioactives destinées à l'inhalation
DK3911298T3 (da) Formuleringer
MA52874A (fr) Formulations/compositions comprenant de l'ibrutinib
MA50241A (fr) Formulations topiques de chloroprocaïne
CR20220587A (es) Formulaciones farmacéuticas
IT201900022029A1 (it) Formulazioni oftalmiche
UA42137S (uk) Культиватор навісний
UA42136S (uk) Культиватор навісний
ES1210466Y (es) Prenda intima de proteccion para practicas sexuales
UA40217S (uk) Борона-лущильник «ерідан-4000»
UA41391S (uk) Культиватор навісний
MA49557A (fr) Formulations à action prolongée
UA41909S (uk) Культиватор